However, because the 18F-FDG PET analytical methods are diverse in terms of lesion selection (such as single or multiple), the definition of the volume of interest (VOI), selected parameters (such as standardized uptake value [SUV] or total lesion glycolysis [TLG]), and response criteria [22,23,24,25,26,27,28,29], there is lack of uniform consensus of the use of 18F-FDG PET/CT in patients with lung cancer treated with EGFR-TKIs. This evidence concerns the gene EGFR and lung carcinoma.